Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793995

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1793995

Hydroxyzine

PUBLISHED:
PAGES: 284 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Hydroxyzine Market to Reach US$660.3 Million by 2030

The global market for Hydroxyzine estimated at US$516.8 Million in the year 2024, is expected to reach US$660.3 Million by 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Histamine-Mediated Pruritus Indication, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$387.8 Million by the end of the analysis period. Growth in the Urticaria Indication segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$140.8 Million While China is Forecast to Grow at 7.7% CAGR

The Hydroxyzine market in the U.S. is estimated at US$140.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$135.6 Million by the year 2030 trailing a CAGR of 7.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.4% CAGR.

Global Hydroxyzine Market - Key Trends and Drivers Summarized

Why Is Hydroxyzine a Widely Prescribed Medication in Modern Therapeutic Protocols?

Hydroxyzine has become a frequently utilized medication across various branches of clinical medicine due to its versatile pharmacological profile. Originally developed as an antihistamine, hydroxyzine has expanded in application and is now commonly prescribed not only for allergic reactions but also for anxiety, nausea, sleep disturbances, and pruritus. Its dual action as both an H1 receptor antagonist and a central nervous system depressant allows it to be effective in treating symptoms across multiple systems. Physicians often turn to hydroxyzine as a non-benzodiazepine alternative for patients who require short-term relief from anxiety or agitation, particularly those with a history of substance abuse where traditional anxiolytics may pose a higher risk. It is also commonly prescribed in preoperative settings to ease anxiety and produce mild sedation. In dermatology, hydroxyzine is favored for its antipruritic effects and ability to manage chronic urticaria and dermatitis-related itch. Furthermore, the medication’s antiemetic properties make it useful for treating motion sickness and nausea related to chemotherapy or postoperative recovery. The wide range of indications and relatively low risk of addiction has made hydroxyzine a staple in outpatient and inpatient care settings alike. Its oral and intramuscular formulations offer flexibility depending on the urgency of treatment or the patient’s ability to take medications orally. Pediatricians and geriatric specialists alike find hydroxyzine to be a valuable tool, provided it is used with appropriate dosing and monitoring. As healthcare providers increasingly look for medications that offer multi-symptom relief without the complex risk profiles of controlled substances, hydroxyzine remains an appealing choice in therapeutic planning.

How Do Pharmacological Properties and Safety Profiles Influence Its Clinical Utility?

The pharmacological characteristics of hydroxyzine play a significant role in its ongoing popularity among clinicians. One of its most notable features is its ability to cross the blood-brain barrier and exert calming effects through modulation of activity in the central nervous system. Unlike traditional sedatives or anxiolytics that directly affect GABA receptors, hydroxyzine exerts its calming influence by antagonizing histamine receptors and reducing neuronal excitability. This unique mechanism allows it to deliver anxiolytic and sedative effects without the typical dependence and tolerance issues that often accompany benzodiazepines. The drug has a rapid onset of action, typically taking effect within 15 to 30 minutes after oral administration, which is particularly useful in acute anxiety episodes or allergic reactions. While hydroxyzine is generally well tolerated, certain precautions are necessary, especially in patients with liver or kidney impairment, since the drug is metabolized hepatically and excreted renally. Side effects such as drowsiness, dry mouth, dizziness, and occasionally blurred vision are common but typically mild and transient. Importantly, hydroxyzine does not interfere with cognitive or motor functions to the same extent as other sedatives, making it a safer option for individuals who must remain relatively alert. Cardiac monitoring may be advised in patients with known heart conditions due to the potential for QT interval prolongation in high doses or when combined with other medications. Its non-habit-forming nature adds to its value in long-term care environments where chronic symptom management is necessary. Overall, hydroxyzine's well-established safety profile, broad spectrum of action, and relatively low cost contribute to its enduring relevance in modern clinical practice.

What Therapeutic Trends Are Shaping the Demand for Hydroxyzine in Global Healthcare?

Global trends in mental health awareness, chronic disease management, and multi-symptom therapy are all contributing to sustained demand for hydroxyzine. The increasing prevalence of anxiety disorders, driven by societal stress, economic instability, and post-pandemic mental health challenges, has led many healthcare providers to seek fast-acting, non-addictive alternatives to manage symptoms in diverse populations. Hydroxyzine fits this requirement, offering symptomatic relief with fewer concerns about misuse. At the same time, allergy-related conditions such as rhinitis, eczema, and hives are on the rise, particularly in urban environments with high pollution levels. The antihistamine properties of hydroxyzine make it a suitable option for patients requiring both allergic symptom control and relief from associated anxiety or insomnia. In oncology and palliative care settings, hydroxyzine is increasingly incorporated into supportive care protocols to manage nausea, vomiting, and general discomfort. Its dual utility in both physical and psychological symptom relief enhances its value in multidisciplinary treatment plans. Additionally, hydroxyzine’s off-label use in treating certain behavioral symptoms, including agitation and irritability in patients with dementia or developmental disorders, is becoming more common. The growing shift toward personalized and integrative medicine is also pushing clinicians to adopt medications that address multiple symptoms with a single compound, minimizing polypharmacy risks. With healthcare systems focusing on cost-effective, broad-spectrum medications, hydroxyzine remains attractive for formulary inclusion. In many developing countries, where access to advanced psychiatric or dermatologic drugs may be limited, hydroxyzine serves as a reliable and affordable first-line option. These broader therapeutic trends are helping solidify its position as a core medication in both specialty and primary care environments.

What Factors Are Contributing to the Continued Growth of the Hydroxyzine Market Globally?

The global hydroxyzine market is expanding due to a combination of clinical utility, affordability, regulatory support, and increasing healthcare demands across both developed and emerging markets. One major driver is the growing global burden of mental health conditions and allergic diseases, which require versatile treatment options that can be deployed quickly and safely. Hydroxyzine, with its multifaceted applications, has gained favor among practitioners who manage complex cases where patients present with overlapping symptoms. The affordability of hydroxyzine, particularly in its generic forms, makes it an accessible treatment option in public health systems and low-resource settings. Additionally, the widespread approval of hydroxyzine by regulatory bodies in numerous countries facilitates its distribution through both government-run healthcare programs and private providers. Pharmaceutical companies are continuing to invest in new formulations, including extended-release versions and combination therapies, to cater to evolving consumer preferences and clinical needs. The rise in telemedicine and digital prescribing platforms has also played a role, as medications like hydroxyzine that are widely understood and have a strong safety record are frequently chosen for remote prescriptions. Hospitals and outpatient clinics increasingly favor hydroxyzine in treatment protocols because of its predictable effects and compatibility with other therapies. In pediatric and geriatric care, where polypharmacy risks are higher, hydroxyzine’s single-agent efficacy is a key advantage. Market growth is further supported by educational initiatives aimed at reducing the stigma associated with mental health treatment, which in turn is encouraging more individuals to seek medical support for anxiety, insomnia, and related conditions. As a result of these factors, hydroxyzine continues to see steady demand and market penetration globally, with prospects for sustained expansion as healthcare systems adapt to the rising need for comprehensive, accessible, and cost-effective pharmacological solutions.

SCOPE OF STUDY:

The report analyzes the Hydroxyzine market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication Type (Histamine-Mediated Pruritus Indication, Urticaria Indication, Atopic Contact Dermatitis Indication); Dosage Form (Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form, Syrup Dosage Form)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma Ltd.
  • Cadila Pharmaceuticals Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Endo International plc
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Ltd.
  • Lupin Limited
  • Mylan N.V. (Viatris)
  • Perrigo Company plc
  • Pfizer Inc.
  • Sandoz (a Novartis division)
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Unichem Laboratories Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37147

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Hydroxyzine - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Anxiety and Allergic Conditions Throws the Spotlight on Hydroxyzine as a Versatile Therapeutic Agent
    • Increased Preference for Non-Benzodiazepine Anxiolytics Propels Growth in Hydroxyzine Prescriptions
    • Here's the Story: Expanding Off-Label Use in Sleep Disorders and Itching Strengthens the Business Case for Hydroxyzine
    • Growing Demand for Pediatric Allergy Treatments Drives Adoption in Liquid and Syrup Formulations
    • Cost-Effective Generic Availability Sustains Widespread Use Across Primary Care and Psychiatry Settings
    • Integration into Multimodal Treatment Plans Enhances Demand in Dermatology and Palliative Care
    • Rising Incidence of Urticaria and Atopic Dermatitis Expands Addressable Market for Antihistamine-Based Therapies
    • Preference for Sedating Antihistamines in Acute Episodes Fuels Short-Term Use Cases for Hydroxyzine
    • Global Generic Drug Expansion and Local Manufacturing Capabilities Drive Accessibility in Emerging Markets
    • Formulation Innovations and Extended-Release Research Open Future Opportunities in Dosing Convenience
    • Telehealth and E-Prescription Models Support Continued Market Presence in Remote and Mental Health Care Settings
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Hydroxyzine Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Hydroxyzine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Histamine-Mediated Pruritus Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Histamine-Mediated Pruritus Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Urticaria Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Urticaria Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Atopic Contact Dermatitis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Atopic Contact Dermatitis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tablets Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tablets Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Capsules Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Capsules Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Injection Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Injection Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Syrup Dosage Form by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Syrup Dosage Form by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • JAPAN
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • CHINA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • EUROPE
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hydroxyzine by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • FRANCE
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • GERMANY
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Hydroxyzine by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • INDIA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Hydroxyzine by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Hydroxyzine by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Hydroxyzine by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030
  • AFRICA
    • Hydroxyzine Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Hydroxyzine by Indication Type - Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Hydroxyzine by Indication Type - Percentage Breakdown of Value Sales for Histamine-Mediated Pruritus Indication, Urticaria Indication and Atopic Contact Dermatitis Indication for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Hydroxyzine by Dosage Form - Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Hydroxyzine by Dosage Form - Percentage Breakdown of Value Sales for Tablets Dosage Form, Capsules Dosage Form, Injection Dosage Form and Syrup Dosage Form for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!